top of page

Align Summit: Allston based KiraGen Bio is aiming to program CAR-T cells to tune out the suppressive nature of the tumor micro environment. The first program will be for GBM.

  • blonca9
  • Oct 7
  • 1 min read

Co-Founder and CEO Aaron Edwards describes the rational behind this approach, as opposed charging the cells with cytokines or removing their brakes. He also explains why KiraGen is looking abroad to do its first clinical trials.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page